Mirtazapine

Summary

Mirtazapine (CHEMBL654) is an approved small-molecule α-adrenergic antagonist (ATC N06AX11) targeting ADRA2A, ADRA2B, and ADRA2C; indicated across 23 conditions including major depressive disorder and depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX11
• Targets: 5 (ADRA2A, ADRA2B, ADRA2C…)
• Indications: 23 conditions
• Clinical trials: 82
• Chemistry: 265.35 Da · C17H19N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL654
Name	Mirtazapine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4205
ChEBI	CHEBI:6950
ATC	N06AX11
Molecular formula	C17H19N3
Molecular weight	265.35
InChIKey	RONZAEMNMFQXRA-UHFFFAOYSA-N

SMILES: CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4

IUPAC name: 5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene

Pharmacological roles (ChEBI): α-adrenergic antagonist, serotonergic antagonist, histamine antagonist, anxiolytic drug, H1-receptor antagonist, oneirogen.

Also known as: Avanza, Mirataz, Mirtazapin, Mirtazapina, Mirtazapine, Mirtazapine anhydrous, Norset, ORG 3770, ORG-3770, Promyrtil, Remeron, Remeron soltab

Parent form; salt/anhydrous children: CHEMBL5315116

Patent coverage: 5,893 distinct patent families (20,324 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 20,239 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA2A	α2A-adrenoceptor	Antagonist	7.1	0.1%	P08913
ADRA2B	α2B-adrenoceptor	Antagonist	6.7	0.2%	P18089
ADRA2C	α2C-adrenoceptor	Antagonist	6.7	0%	P18825
HTR2A	5-HT2A receptor	Antagonist	7.16	0%	P28223
HTR2C	5-HT2C receptor	Antagonist	7.41	0%	P28335

Broader ChEMBL bioactivity targets: 26 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 3A, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Thyrotropin receptor, Beta-lactamase, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2.

Bioactivity

ChEMBL activities: 37 potent at pChembl ≥ 5 of 43 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	8.8	Ki	1.6	nM	CHEMBL_ACT_1518470
P14842	8.7	Ki	2	nM	CHEMBL_ACT_1066122
P08909	8.26	Ki	5.5	nM	CHEMBL_ACT_1066123
HRH1	8.19	AC50	6.5	nM	CHEMBL_ACT_25212907
HTR2A	8.09	Ki	8.2	nM	CHEMBL_ACT_19101891
P14842	7.83	Ki	14.8	nM	CHEMBL_ACT_459720
ADRA2C	7.75	Ki	18	nM	CHEMBL_ACT_1518457
HTR1A	7.75	Ki	18	nM	CHEMBL_ACT_19101892
ADRA2A	7.7	Ki	20	nM	CHEMBL_ACT_1518456
HTR2C	7.41	Ki	39	nM	CHEMBL_ACT_1518468
CYP2C19	7.3	Potency	50.1	nM	CHEMBL_ACT_4006301
CYP2C9	7.3	Potency	50.1	nM	CHEMBL_ACT_5033462
CYP2C9	7.3	AC50	50.12	nM	CHEMBL_ACT_6002426
CYP2C19	7.3	AC50	50.12	nM	CHEMBL_ACT_6044291
HTR2A	7.16	Ki	69	nM	CHEMBL_ACT_1518466
ADRA2A	7.07	IC50	85.11	nM	CHEMBL_ACT_983880
ADRA2C	6.7	IC50	199.5	nM	CHEMBL_ACT_983882
ADRA2B	6.65	IC50	223.9	nM	CHEMBL_ACT_983881
HTR7	6.58	Ki	265	nM	CHEMBL_ACT_1518467
HTR2A	6.46	AC50	350	nM	CHEMBL_ACT_25225527
ADRA2A	6.41	AC50	388.3	nM	CHEMBL_ACT_25157092
CYP2D6	6.3	Potency	501.2	nM	CHEMBL_ACT_5006422
CYP2D6	6.3	AC50	501.2	nM	CHEMBL_ACT_6067216
ADRA2C	6.25	AC50	555.6	nM	CHEMBL_ACT_25148275
P15823	6.22	Ki	608	nM	CHEMBL_ACT_1518471
P15823	5.98	Ki	1050	nM	CHEMBL_ACT_1066125
ADRA2B	5.85	AC50	1400	nM	CHEMBL_ACT_25144085
P61169	5.84	Ki	1460	nM	CHEMBL_ACT_1066117
ADRA2A	5.8	AC50	1600	nM	CHEMBL_ACT_25220265
HTR3A	5.54	Ki	2900	nM	CHEMBL_ACT_13489298

Target pathways

Aggregated over 5 target gene(s): ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C.

Top Reactome pathways

21 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
Signaling by GPCR	5	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
Class A/1 (Rhodopsin-like receptors)	5	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
Amine ligand-binding receptors	5	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
GPCR downstream signalling	5	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
GPCR ligand binding	5	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
Hemostasis	3	ADRA2A, ADRA2B, ADRA2C
Adrenoceptors	3	ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor	3	ADRA2A, ADRA2B, ADRA2C
G alpha (i) signalling events	3	ADRA2A, ADRA2B, ADRA2C
G alpha (z) signalling events	3	ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation	3	ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)	3	ADRA2A, ADRA2B, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Serotonin receptors	2	HTR2A, HTR2C
Metabolism of proteins	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
G alpha (q) signalling events	2	HTR2A, HTR2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	5
signal transduction	5
epidermal growth factor receptor signaling pathway	3
negative regulation of norepinephrine secretion	3
regulation of vasoconstriction	3
platelet activation	3
negative regulation of epinephrine secretion	3
positive regulation of MAPK cascade	3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	3
adrenergic receptor signaling pathway	3
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	3
regulation of smooth muscle contraction	3
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	2
female pregnancy	2
positive regulation of cell population proliferation	2

Indications & clinical

Indications

23 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
major depressive disorder	4	MONDO:0002009	MONDO:0002009
depressive disorder	4	MONDO:0002050	MONDO:0002050
insomnia	4	MONDO:0013600	EFO:0004698
autism spectrum disorder	3	MONDO:0005258	EFO:0003756
heroin dependence	3	MONDO:0005367	EFO:0004240
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
cocaine dependence	2	MONDO:0005186	EFO:0002610
fibromyalgia	2	MONDO:0005546	EFO:0005687
drug dependence	2	MONDO:0005303	EFO:0003890
substance-related disorder	2	MONDO:0002494	MONDO:0002491
methamphetamine dependence	2	MONDO:0005419	EFO:0004701
alcohol abuse	2	MONDO:0002046	MONDO:0007079
anorexia nervosa	2	MONDO:0005351	MONDO:0005351
paraganglioma	2	MONDO:0000448	EFO:1000453
obstructive sleep apnea syndrome	1	MONDO:0007147	EFO:0003918
stomach disorder	1	MONDO:0004298	EFO:0009608

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 82.

Phase distribution

Phase	Trials
PHASE4	24
PHASE2	24
Not specified	14
PHASE3	9
PHASE1	5
EARLY_PHASE1	4
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00021528	PHASE4	COMPLETED	Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
NCT00150839	PHASE4	COMPLETED	Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
NCT00177567	PHASE4	COMPLETED	Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
NCT00288782	PHASE4	COMPLETED	PET Neuroimaging of [11C]Mirtazapine
NCT00302107	PHASE4	COMPLETED	A Placebo-Controlled Study of Mirtazapine for PTSD
NCT00590863	PHASE4	COMPLETED	Combining Medications to Enhance Depression Outcomes
NCT00926835	PHASE4	TERMINATED	Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients
NCT01109693	PHASE4	COMPLETED	Strategic Use of New Generation Antidepressants for Depression
NCT01178671	PHASE4	COMPLETED	Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
NCT01240096	PHASE4	COMPLETED	Mirtazapine Versus Placebo in Functional Dyspepsia
NCT01263080	PHASE4	COMPLETED	Evaluation of Mirtazapine and Folic Acid for Schizophrenia:
NCT01458626	PHASE4	COMPLETED	Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement
NCT01465919	PHASE4	TERMINATED	Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
NCT01601002	PHASE4	COMPLETED	LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
NCT01764867	PHASE4	UNKNOWN	Algorithm Guided Treatment Strategies for Major Depressive Disorder
NCT02191124	PHASE4	COMPLETED	The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial
NCT03219008	PHASE4	UNKNOWN	Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
NCT03675555	PHASE4	COMPLETED	Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering
NCT03679052	PHASE4	COMPLETED	Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering
NCT04013386	PHASE4	COMPLETED	Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting
NCT04155008	PHASE4	TERMINATED	Nutrition and Pharmacological Algorithm for Oncology Patients Study
NCT04908605	PHASE4	COMPLETED	Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine
NCT05108688	PHASE4	COMPLETED	Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache
NCT05978219	PHASE4	COMPLETED	Efficacy of Mirtazapine in Major Depressive Disorder With Insomnia
NCT00080158	PHASE2/PHASE3	COMPLETED	Treatment of Adolescent Suicide Attempters (TASA)
NCT00782405	PHASE3	COMPLETED	Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01867775	PHASE3	UNKNOWN	Mirtazapine for Sleep Disorders in Alzheimer’s Disease
NCT02336750	PHASE3	COMPLETED	Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT02541526	PHASE3	UNKNOWN	Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia
NCT03031184	PHASE3	COMPLETED	Study of Mirtazapine for Agitation in Dementia
NCT03852160	PHASE3	WITHDRAWN	A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
NCT04763135	PHASE3	TERMINATED	Mirtazapine in Cancer-related Poly-symptomatology
NCT00488072	PHASE2	ACTIVE_NOT_RECRUITING	Effects of Mirtazapine on Appetite in Advanced Cancer Patients
NCT03935685	PHASE2	ACTIVE_NOT_RECRUITING	Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
NCT05170919	PHASE2	ENROLLING_BY_INVITATION	Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer
NCT06309472	PHASE2	RECRUITING	Trial of Mirtazapine for Depression in IBD
NCT06323837	PHASE2	RECRUITING	Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
NCT06530290	PHASE2	RECRUITING	Evaluating the Effect of Mirtazapine on Anxiety in Parkinson’s Disease Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (2) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for mirtazapine and CYP2D6	DPWG	CYP2D6
Annotation of DPWG Guideline for mirtazapine and CYP2C19	DPWG	CYP2C19

PharmGKB also curates 10 clinical and 33 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

755 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CHENODIOL	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
BENFLUOREX	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
BENZQUINAMIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
BENZTROPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CLONIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DOTHIEPIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
DROPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
ECONAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
GUANABENZ	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
GUANFACINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
HALOPROGIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
ILOPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
IPRINDOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
LORCASERIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
LURASIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
MAPROTILINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
METHYLERGONOVINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
METHYSERGIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
NEBIVOLOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C